Metabolism of the chloroethylnitrosoureas
- PMID: 1949908
- DOI: 10.3109/00498259109039517
Metabolism of the chloroethylnitrosoureas
Abstract
1. The chemical degradation and metabolism of the 2-chloroethylnitrosoureas (CENUSs) have been critically reviewed with the objective of gaining a better understanding of factors that could aid in the design of new, more effective, anticancer drugs. 2. The CENUs are chemically unstable under normal physiological conditions and can rapidly degrade to give a variety of reactive intermediates capable of carbamoylating proteins and/or alkylating both proteins and DNA. 3. Carbamoylation is thought to make a minimal contribution to the cytotoxic effect of the CENUs, although it may be involved in some of the unwanted side-effects. It would seem desirable, therefore, to design new CENUs with low carbamoylating activity. 4. The main action of the CENUs is by alkylation of DNA via a chloroethyldiazo-hydroxide intermediate. Chloroethylation is important, as opposed to hydroxyethylation, since the former leads to inter-strand DNA cross-linking via an intramolecular rearrangement with the removal of chloride. It is this inter-strand cross-linking which prevents subsequent DNA repair and loss of cytotoxicity. 5. Metabolism usually, although not exclusively, leads to deactivation of the CENUs either by dechlorination or denitrosation of the molecule, generally with the former being the dominant route. These reactions occur very rapidly, and before chemical degradation can take place, and can be an important determinant in the final cytotoxicity. Moreover, both these pathways involve the cytochrome P-450 system and can be induced with phenobarbital.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Investigation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas.Cancer Res. 1985 Aug;45(8):3460-4. Cancer Res. 1985. PMID: 3860285
-
DNA damage and repair in the bone marrow of rats treated with four chloroethylnitrosoureas.Cancer Res. 1984 Feb;44(2):514-8. Cancer Res. 1984. PMID: 6229329
-
Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione.Cancer Res. 1989 Oct 1;49(19):5258-61. Cancer Res. 1989. PMID: 2766294
-
The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level.Cancer Invest. 1997;15(6):588-98. doi: 10.3109/07357909709047601. Cancer Invest. 1997. PMID: 9412665 Review.
-
Biochemical and pharmacologic properties of nitrosoureas.Cancer Treat Rep. 1981;65 Suppl 3:119-24. Cancer Treat Rep. 1981. PMID: 7049367 Review.
Cited by
-
Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells.Vet Sci. 2015 Apr 24;2(2):52-68. doi: 10.3390/vetsci2020052. Vet Sci. 2015. PMID: 29061931 Free PMC article.
-
Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.Cancer Chemother Pharmacol. 1992;31(2):118-22. doi: 10.1007/BF00685097. Cancer Chemother Pharmacol. 1992. PMID: 1451232
-
BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line.Cancer Chemother Pharmacol. 2009 Mar;63(4):753-8. doi: 10.1007/s00280-008-0792-9. Epub 2008 Jul 17. Cancer Chemother Pharmacol. 2009. PMID: 18633619 Free PMC article.
-
Alleviation of 1,N6-ethanoadenine genotoxicity by the Escherichia coli adaptive response protein AlkB.Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):755-60. doi: 10.1073/pnas.0607377104. Epub 2007 Jan 9. Proc Natl Acad Sci U S A. 2007. PMID: 17213319 Free PMC article.
-
Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas.Cancer Chemother Pharmacol. 1993;32(1):46-52. doi: 10.1007/BF00685875. Cancer Chemother Pharmacol. 1993. PMID: 8462123 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources